Search the Newsreel

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival WILMINGTON, Del., September 25, 2026--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted …

AstraZeneca Gets US FDA Priority Review for Investigative Bladder Cancer Therapy

AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market?

AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival (PFS) in patients with upfront first-line ER-positive, HER2-negative advanced breast cancer. While the regimen …

AstraZeneca granted EU label expansion for COPD therapy, Trixeo in asthma

[AstraZeneca company office building] Robert Way/iStock Editorial via Getty Images * AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Wednesday announced that the European Commission approved its inhaler therapy Trixeo Aerosphere as a late-line maintenance option for patients aged 12 years and older with asthma, expanding the drug's …

AstraZeneca's Trixeo Secures Approval for Asthma in the EU

AstraZeneca AZN announced that the European Commission has approved its respiratory drug, Trixeo Aerosphere, for a new indication. The drug is approved in the European Union (EU) as a maintenance treatment for previously treated asthma patients aged 12 years and older who are not …

AstraZeneca (LSE:AZN) Gets EU Support For Two Key Drugs

AstraZeneca (LSE:AZN) received positive opinions from the EMA's CHMP for Enhertu and Klygefa in the European Union. The CHMP backed Enhertu as an adjuvant treatment option for early-stage HER2-positive breast cancer with high risk of recurrence. The committee also supported Klygefa as an add-on …

AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’

Britain's biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research. AstraZeneca and GSK, along with European rivals Novo Nordisk, Sanofi, Roche and Novartis, wrote an open letter warning …

AstraZeneca (LSE:AZN) Stock May Be 48% Undervalued On Enhertu Trial Progress

AstraZeneca has ridden a strong five year share price run and a steady stream of oncology and respiratory trial updates, which raises a simple question for investors who care about valuation. Is the current price around £125.60 broadly in line with what the company's …

AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England

AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo's Enhertu has been cleared for use by England's National Health Service (NHS) for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE's revised recommendation follows changes to drug valuation …

Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note

Astrazeneca (AZN) closed at $168.10 in the latest trading session, marking a +1.22% move from the prior day. This change lagged the S&P 500's 1.49% gain on the day. On the other hand, the Dow registered a gain of 0.71%, and the technology-centric Nasdaq …

AstraZeneca's Alexion Gets Positive EU Recommendation for Klygefa in Rare Muscle Disease

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?

AstraZeneca's AZN stock has taken a beating recently, with the company facing several pipeline setbacks in the past few months. AZN's Recent Pipeline Setbacks In July, AstraZeneca announced the failure of a phase III study evaluating Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy …

AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer

AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug

AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success

AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as …

AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed

On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease. It shows the treatment reduced moderate and severe flare-ups by roughly 30% across a broad patient …

Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)

Onco360 Oncology Pharmacy LOUISVILLE, Ky., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca for Etcamah™ (camizestrant), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, …

AstraZeneca Gains as Enhertu Clears England's Value Gate

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, secured a major access win for Enhertu in England after the NHS reversed an earlier cost-effectiveness rejection, Reuters reported Thursday. The U.S. shares climbed approximately 1.3% to $165.04, based on the …

AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts

On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)'s camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer. Even though an FDA advisory panel voted in April that the drug lacked patient benefit. …

AstraZeneca's Enhertu Breast Cancer Drug Gets UK Recommendation

AstraZeneca Shares Rise as J.P. Morgan Stays Overweight

This article first appeared on GuruFocus. AstraZeneca plc (NYSE:AZN) rose 2.16% intraday after J.P. Morgan reiterated an Overweight rating, pointing to six Phase III readouts due in 2027 that together carry more than $10 billion in risk-adjusted peak sales. The bank argues they should …

AstraZeneca shares oversold after trial flops and merger talk, says UBS

AstraZeneca shares oversold after trial flops and merger talk, says UBS Proactive uses images sourced from Shutterstock UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker …

Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before …

AstraZeneca's news flow next year could sustain drugs group beyond 2030, says leading bank

AstraZeneca's news flow next year could sustain drugs group beyond 2030, says leading bank Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) offers the richest run of drug news in the pharmaceuticals sector over the next 18 months, according to JP Morgan, …

Pipeline de AstraZeneca: seis datos de 2027 que podrían cambiar su crecimiento

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss

AstraZeneca PLC (NYSE:AZN)'s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, dealing a setback to one of the company's key oncology growth opportunities. The trial evaluated Etcamah plus Pfizer's Ibrance (palbociclib) in previously untreated patients …

Why the Market Dipped But Astrazeneca (AZN) Gained Today

In the latest close session, Astrazeneca (AZN) was up +2.25% at $163.78. The stock's change was more than the S&P 500's daily loss of 0.48%. Elsewhere, the Dow lost 0.29%, while the tech-heavy Nasdaq lost 0.56%. Prior to today's trading, shares of the pharmaceutical …

Why Is AstraZeneca Stock Trading Higher Today?

AstraZeneca Plc(NYSE:AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in lung cancer treatments alongside mixed findings in advanced breast cancer research. Long-Term Survival Gains In Early-Stage Lung Cancer Eight-year follow-up data released on Monday from the ADAURA Phase …

AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment

* AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) recently approved Etcamah (camizestrant) failed in a phase 3 trial as a first-line treatment in combination with Pfizer's (PFE [https://seekingalpha.com/symbol/PFE]) Ibrance (palbociclib) for HR+, HER2- breast cancer. * Results from the SERENA-4 trial showed that the combination did not improve …

AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer

AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster. Continue Reading

Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion?

AstraZeneca plc (NASDAQ:AZN) is exploring whether one of its biggest cancer drugs can work better with a carefully selected partner. A late-stage trial found that combining Tagrisso with Orpathys significantly extended the time patients lived without their disease worsening compared with Tagrisso alone. The …

AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche

AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drew praise from Deutsche Bank for tozorakimab's lung disease data, but the broker paired its positive assessment with a bearish verdict on the shares. …